Abstract
Calcium-channel blocking agents, which include nifedipine, verapamil, and diltiazem, have recently been licensed for use in this country. Calcium antagonists are a heterogeneous group of agents with dissimilar structural, electrophysiologic, and pharmacologic properties. 1 The chemical structures of the most commonly used calcium blocking agents (nifedipine, verapamil, and diltiazem) differ and the molecular basis of their action remains unknown. These agents not only have established beneficial effects in the treatment of cardiovascular diseases, but also serve as valuable research tools to elucidate the role of calcium flux in health and disease. Since many pathophysiologic events that underlie bronchial asthma and hyperreactive airway disease are calcium-dependent phenomena, it is possible that calcium antagonists may prove useful in both the therapy and prophylaxis of these conditions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
